Knopp Biosciences Receives Key Patent Directed to Ion Channel Activators for Brain Disorders
January 26, 2017
PITTSBURGH, PA, USA—January 26, 2017—Knopp Biosciences LLC today announced it has received United States Patent No. 9,481,653 entitled "Benzoimidazol-1,2-yl amides as Kv7 channel activators."
The patent relates to the company's discovery program in neonatal epileptic encephalopathy and other seizure disorders, for which novel treatments are urgently needed. Issued claims are directed to a series of orally available small molecules and their use in treating epilepsy, neuropathic pain, and other neurological disorders.
"This initial patent awarded to our ion channels program greatly strengthens our efforts to develop novel treatments for epilepsy, focused initially on newborns and children with profound seizure disorders," said Michael Bozik, M.D., president and CEO of Knopp. "The patent also recognizes the creativity and collaboration of our medicinal chemistry and biology teams, which work seamlessly to solve the complexity of Kv7 biology and pharmacology."
Dysfunction of voltage-gated potassium channels of the Kv7 family is linked to nerve-cell excitability implicated in a range of diseases. Knopp expects initially to advance its lead Kv7 activators in a rare disorder associated with inherited mutations in the KCNQ2 gene, which provides instructions for making a brain Kv7 channel. Certain of these mutations cause severe epilepsy and profound developmental disability in newborns and infants, for whom conventional anti-seizure medications are insufficient or ineffective.
Knopp has pending a number of additional patents directed to compositions for activating ion channels.
ABOUT KNOPP BIOSCIENCES LLC
Knopp Biosciences, based in Pittsburgh, PA, USA, is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need in clearly defined patient populations. Our clinical-stage small molecule, dexpramipexole, will be entering Phase 2/3 clinical studies in hypereosinophilic syndromes and Phase 2 clinical studies in eosinophilic asthma. Our preclinical platform is directed to small molecule treatments for neonatal epileptic encephalopathy, a devastating brain disorder of infants caused by a rare mutation in the KCNQ2 gene.
This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs for dexpramipexole. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that dexpramipexole will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market the product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.
Thomas Petzinger Jr.